Official Title: “Candesartan in Heart Fail. Assess. of Reduction in Mortality & Morbidity. Candesartan in Patients With Heart Failure Who Are ACE Inhibitor Intolerant and Have Depressed Left Ventricular Systolic Function”

A study to evaluate the effect of Atacand on patients with heart failure with depressed left ventricular function

Study Type: Interventional

Study Design: Treatment, Randomized, Double-Blind, Parallel Assignment, Efficacy Study

Study Primary Completion Date: March 2003

Intervention(s) in this Clinical Trial

• Drug: Candesartan
• Drug: Placebo

Arms, Groups and Cohorts in this Clinical Trial

• Active Comparator: 1
• Placebo Comparator: 2

Primary Measures

• Cardiovascular mortality or hospitalisation due to congestive heart failure
  • Time Frame: 2, 4, 6 weeks, 6 months, every 4 months thereafter until 24 months
    

Secondary Measures

• Cardiovascular mortality or hospitalisation for management of congestive heart failure, or non fatal MI
  • Time Frame: 2, 4, 6 weeks, 6 months, every 4 months thereafter until 24 months
    

Inclusion Criteria:

• Male or female aged 18 or above
• Congestive Heart Failure with symptoms for more than 4 weeks before starting study
• Provision of informed consent

Exclusion Criteria:

• Current low blood pressure with symptoms
• Liver disease considered significant by the study doctor
• Pregnant or lactating females

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Lead Sponsor: AstraZeneca

Overall Clinical Trial Officials and Contacts

Chris Granger, MD Principal Investigator   

Information obtained from ClinicalTrials.gov on July 02, 2009

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00634400

Study ID Number: SH-AHS-0003

ClinicalTrials.gov Identifier: NCT00634400

Health Authority: Australia: Department of Health and Ageing Therapeutic Goods Administration